Andres Cervantes
@AndresC27622123
Professor Medical Oncologist at Hospital University of Valencia. Scientific director @Incliva_iis Associate editor @ESMO_OPEN @Annals_Oncology President @myESMO
ID:1139490581779030017
14-06-2019 11:11:40
2,4K Tweets
4,1K Followers
321 Following
⭐️The world of oncology converges in Zurich, Switzerland ! Such an amazing time celebrating & discussing cutting edge science to brainstorm for the greatest oncology meeting ever ESMO - Eur. Oncology Toni Choueiri, MD Sumanta K. Pal, MD, FASCO Myriam Chalabi OncoAlert OncoDaily
Now that the educationals are all set, looking forward to next year’s scientific content! But first: #ESMO24 !
Filippo Pietrantonio Lizza Hendriks and many more!
What happens in Zurich….goes to #ESMO25 ! Fantastic meeting and discussions for the educations, together with my scientific co-chair Toni Choueiri, MD ! New tracks, new concepts and the best experts! Mark your agendas for #Berlin ! ESMO - Eur. Oncology
Endoscopic variceal ligation vs propranolol for prevention of oesophageal variceal bleeding in HCC
Gut Journal
doi.org/10.1136/gutjnl…
🔎🇹🇼phs-II: HCC + medium/large varices
👉EVL is superior to PPL in preventing initial EVB
👉No differences in EVB + OS in BCLC C/D
‼️No treatment…
Pleased to share PAGA guideline for #gastriccancer . Really appreciate Asian & European experts Lizzy Smyth Tania Fleitas Kanonnikoff George Pentheroudakis Andres Cervantes who joined the discussion. Thank you ESMO - Eur. Oncology and 日本臨床腫瘍学会（JSMO） for excellent support. esmoopen.com/article/S2059-…
#openaccess in Annals of Oncology, Jean-Yves Blay and coll. report on the impact on patient outcomes of the implementation of NETSARC, a nationwide network of reference sarcoma centers with specialized multidisciplinary tumor boards (MDTBs)
annalsofoncology.org/article/S0923-…
1/2
A neoadjuvant treatment regimen of anti-PD-L1 #immunotherapy followed by anti-PD-L1 + chemotherapy was well tolerated and led to pathologic response rate of 70% in patients with resectable #GastricCancer or GEJ adenocarcinoma Myriam Chalabi The Netherlands Cancer Institute
nature.com/articles/s4159…
Just out on Cancer Treatment Reviews 📢📢📢 Andres Cervantes
@GianlucaMauri1 IEO Fondazione Oncologia Niguarda Onlus
'The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review' cancertreatmentreviews.com/article/S0305-…
⭐️ The American Cancer Society American Cancer Society just published the cancer statistics paper.
👉🏼Meet the amazing person behind the scenes 👉🏼 Dr. Ahmedin Jemal 👉🏼from the Surveillance & Health Equity Science at American Cancer Society Society. He is the man with probably highest impact…
JUST IN: Most cited paper every year in Cancer is out:
Cancer statistics, 2024 in CA: A Cancer Journal for Clinicians
acsjournals.onlinelibrary.wiley.com/doi/10.3322/ca…
American Cancer Society OncoAlert Karen Knudsen, MBA PhD
Check out our latest work, out today in Nature Medicine. Special thanks to Saheli Sadanand for handling our manuscript and for the always fantastic interaction! And to all reviewers Anwaar Saeed (non-anonymous reviewer)for further improving our manuscript The Netherlands Cancer Institute
Landscape of Clinical Resistance Mechanisms to FGFR
Inhibitors in FGFR2+ CCA
Clinical Cancer Research
doi.org/10.1158/1078-0…
🔎82 pts
👉60% with secondary FGFR2 KD mutations
🧐supports strategic sequencing of FGFRi to extend clinical benefit
ESMO - Eur. Oncology EASLnews ILCA Cholangiocarcinoma Foundation #livertwitter
